Passage Bio, Inc. PASG
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -70.76%
- 1 year
- -53.38%
- Open
- 3.61
- Prev close
- 3.52
- Mkt cap
- 11.10M
- Vol
- 7.17K
- Avg vol
- 19.75K
- EPS
- -11.33
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.45
- High
- 3.61
- Forward P/E
- -1.30
- Beta
- 1.20
- Short ratio
- 6.61
- Inst. own
- 59.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 0.6579
- 200-d avg
- 0.93243
- 1y target
- 8.00
Key statistics
- Market cap
- 40.03M
- Enterprise value
- -29.17M
- Trailing P/E
- 0.00
- Forward P/E
- -1.30
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.32
- EPS (TTM)
- -1.17
- Beta
- 1.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -53.04M
- Total cash
- 91.77M
- Total debt
- 26.15M
- Return on equity
- -63.55%
- Shares outstanding
- 61.77M
- Short % of float
- 3.19%
- 50-day average
- 0.6579
- 200-day average
- 0.93243
Analyst view
Consensus: none
- Target (low)
- 4.00
- Target (mean)
- 8.00
- Target (high)
- 13.00
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.24.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.23 | -0.31 | -0.08 | -34.78% |
| Aug 8, 2024 | Jun 1, 2024 | -0.31 | -0.26 | +0.05 | +16.13% |
| Aug 8, 2024 | Jun 1, 2024 | -0.31 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.37 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.37 | -0.30 | +0.07 | +18.92% |
| Mar 4, 2024 | Dec 1, 2023 | -0.41 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 14, 2024 | Canaccord Genuity | main | Buy | Buy |
| Sep 17, 2024 | Canaccord Genuity | reit | Buy | Buy |
| Sep 3, 2024 | Rodman & Renshaw | init | — | Buy |
| May 15, 2024 | Canaccord Genuity | main | Buy | Buy |
| Mar 5, 2024 | Canaccord Genuity | reit | Buy | Buy |
About Passage Bio, Inc.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- passagebio.com
News
- $HAREHOLDER ALERT: The M&A Class Action Firm Launches Investigation for the Merger — BWMN, UTZ , PASG and FNWD
- MERGER VOTE ALERT: The M&A Class Action Firm Is Investigating the Merger Vote -- UTZ, SAFT, PASG and FNWD
- PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders
- PASG Stock Alert: Halper Sadeh LLC is Investigating Whether Passage Bio, Inc. is Obtaining a Fair Price for its Shareholders
- $HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWD
- Passage Bio, Inc. (NASDAQ:PASG) Stock Has Average Price Target of $13.25 According to Brokerages
- Passage Bio (NASDAQ:PASG) Stock Falls 2.4% – Here’s What Happened
- Analysts Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $13.25
- Passage Bio Q2 EPS $(2.44) Beats $(3.47) Estimate
- 12 Health Care Stocks Moving In Thursday's Intraday Session
Your note
Sign in to keep a note on PASG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORTHWICK KATHLEEN | Chief Financial Officer | Sale | Feb 12, 2024 | 28,466 |
| CALE EDGAR B. | General Counsel | Sale | Jan 1, 2024 | 45,995 |
| FORMAN MARK S M.D., PH.D. | Officer | Sale | Feb 12, 2024 | 48,631 |
| FOTOPOULOS ALEXANDROS | Chief Technology Officer | Sale | Jun 15, 2023 | 28,693 |
| KING SIMONA | Chief Financial Officer | Conversion of Exercise of derivative security | Jul 27, 2023 | 23,994 |
| LYNX1 CAPITAL MANAGEMENT LP | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 26, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Orbimed Advisors LLC. | 15.90% | 9,822,876 | 6.37M | Sep 29, 2024 |
| Lynx1 Capital Management Lp | 13.64% | 8,426,955 | 5.46M | Sep 29, 2024 |
| Vestal Point Capital, LP | 9.88% | 6,100,000 | 3.95M | Sep 29, 2024 |
| New Leaf Venture Partners, L.L.C. | 4.04% | 2,497,922 | 1.62M | Sep 29, 2024 |
| Erste Asset Management Gmbh | 3.98% | 2,455,800 | 1.59M | Sep 29, 2024 |
| Vanguard Group Inc | 3.35% | 2,071,538 | 1.34M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.42% | 1,496,581 | 969.93K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.80% | 493,230 | 319.66K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.67% | 416,042 | 269.64K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 294,383 | 190.79K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.23% | 140,100 | 90.80K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.21% | 128,723 | 83.42K | Oct 30, 2024 |